Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • CENTRAL-NERVOUS-SYSTEM  (1)
  • Computertomography  (1)
  • 1
    Keywords: brain ; tumor ; evaluation ; Germany ; imaging ; TUMORS ; TIME ; PATIENT ; primary ; BODY-WEIGHT ; CONTRAST ; INJECTION ; MR ; ACQUISITION ; EFFICACY ; metastases ; PARAMETERS ; STATISTICAL-ANALYSIS ; MORPHOLOGY ; SAFETY ; CENTRAL-NERVOUS-SYSTEM ; CONTRAST AGENTS ; DOUBLE-BLIND ; GADOBENATE-DIMEGLUMINE ; GADODIAMIDE INJECTION ; GADOPENTETATE DIMEGLUMINE ; INTRACRANIAL METASTASES ; gadobenate dimeglumine ; MR imaging ; VASCULARIZATION ; GLIOMAS ; ENHANCED MRI ; brain neoplasms,MR,gadolinium,magnetic resonance (MR),contrast media ; HIGH-DOSE GADOTERIDOL ; MAGNEVIST GD-DTPA
    Abstract: PURPOSE: To evaluate the safety of and compare the enhancement characteristics of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) with those of a standard gadolinium chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany) in primary and secondary brain tumors on the basis of qualitative and quantitative parameters, on an intraindiviual basis.MATERIALS AND METHODS: Twenty-seven patients with either high-grade glioma or metastases were enrolled in a bicentric intraindividual crossover study to compare lesion enhancement with doses of 0.1 mmol per kilogram of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine. MR imaging was performed before injection (T1-weighted spin-echo [SE] and T2-weighted fast SE acquisitions) and at 1, 3, 5, 7, 9, and 16 minutes after injection (T1-weighted SE acquisitions). Qualitative assessment was performed by blinded off-site readers (for 22 patients) and on-site investigators (for 24 patients) in terms of global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference. Additional quantitative assessment with region-of-interest analysis was performed by off-site readers alone. Statistical analysis of qualitative data was performed with the Wilcoxon signed rank test, whereas a nonparametric approach was adopted for analysis of quantitative data.RESULTS: Significant (P 〈 .05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the global assessment of contrast enhancement. For off-site readers I and 2 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patients; and equality was found in five, one, and four patients). Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site investigators for lesion-to-brain contrast and all other qualitative parameters. Off-site quantitative evaluation revealed significantly (P 〈 .05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after injection.CONCLUSION: Significantly superior contrast enhancement of intraaxial enhancing brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopentetate dimeglumine. (C) RSNA, 2004
    Type of Publication: Journal article published
    PubMed ID: 14695387
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1433-0407
    Keywords: Schlüsselwörter Hirninfarkt ; Neuroradiologie ; Computertomographie ; MRT ; Key words Brain infarct ; Neuroradiology ; Computertomography ; MRI
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary At least three questions has to be answered by imaging methods, when new therapies in acute ischemic stroke should be used: 1. Is there a cerebral ischemia? 2. What is the size of the irreversibel damaged tissue and what is the size of the safeable tissue? Is there still a vessel occlusion? New MRI-techniques including MR-angiography, diffusion-weighted imaging and perfusion-MRI, have the potential to de-scribe the status of the brain in detail and to answer these questions. However, the value of these techniques for therapeutical deci-sions (thrombolysis) is unclear and has to be evaluated in clinical studies. Therefore in clinical routine these decisions should still be based on informations from CT and perhaps CT-angiography.
    Notes: Zusammenfassung Um neue Therapien beim arteriellen Schlaganfall optimal einsetzen zu können, müssen in der Akutphase mit den bildgebenden Verfahren drei Fragen beantwortet werden: 1. Liegt eine zerebrale Ischämie vor? 2. Wie groß ist das irreversibel geschädigte und das noch rettbaren Hirngewebe? 3. Liegt noch eine Gefäßokklusion vor? Die neuen magnetresonanztomographischen Techniken (MR-Angiographie, diffusionsgewichtete Bildgebung und Perfusions-MRT) liefern in relativ kurzer Untersuchungszeit eine umfassende Beschreibung des aktuellen Infarktstatus und können prinzipiell diese Fragen beantworten. Die therapeutische Wertigkeit dieser Techniken insbesondere als Entscheidungsgrundlage für eine Thrombolysetherapie muß jedoch noch in klinischen Studien untersucht werden. Bis dahin kann für den klinischen Alltag die Computertomographie evtl. mit der ergänzenden CT-Angiographie als die Methode der Wahl angesehen werden, mit der die therapieentscheidende Infarktdiagnostik durchgeführt werden sollte.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...